Some lung cancer patients may experience durable disease control even after discontinuing immunotherapy

Published Date: 22 Apr 2025

A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due to immune-related adverse events (irAEs) continued to experience long-term disease control, according ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Early Identification of Ovarian Cancer; Allergy Medicine for NSCLC? Unfavorable Development for Anti-TIGIT Medication?

2.

No Laughing Matter: Nitrous Oxide for Transrectal Prostate Biopsy.

3.

Biomarker panel offers hope for early pancreatic cancer detection

4.

Financial hardship common in patients with cancer

5.

New protocols, according to a study, allow many patients to safely return home one day after lung cancer surgery.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot